Company

Verve Therapeutics, Inc.

Headquarters: Cambridge, MA, United States

CEO: Dr. Sekar Kathiresan M.D.

NASDAQ: VERV +0.17%

Market Cap

$440.8 Million

USD as of July 1, 2024

Market Cap History

Verve Therapeutics, Inc. market capitalization over time

Evolution of Verve Therapeutics, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Verve Therapeutics, Inc.

Detailed Description

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is based in Cambridge, Massachusetts.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Verve Therapeutics, Inc. has the following listings and related stock indices.


Stock: NASDAQ: VERV wb_incandescent

Details

Headquarters:

500 Technology Square

Suite 901

Cambridge, MA 02139

United States

Phone: 617-603-0070